Diplomat Pharmacy names new chief executive officer and chairman
11 May 2018 -

Diplomat Pharmacy Inc (NYSE: DPLO), an independent provider of specialty pharmacy services, has named Brian Griffin as its chief executive officer and chairman of the board of directors, effective 4 June 2018, it was reported yesterday.

Griffin was executive vice president and CEO of IngenioRx, the pharmacy benefit manager of Anthem Inc (NYSE: ANTM). He served in positions of increasing responsibility with Medco Health Solutions Inc, including as president, International and Subsidiaries of Express Scripts International Holding Company Inc, which completed its merger with Medco Health Solutions Inc in April 2012, CEO of Medco International BV and CEO of Medco Celesio, BV. Prior to that, he served as group president of Health Plans at Medco Health Solutions Inc, and was responsible for national and regional health plans, BlueCross BlueShield plans, commercial insurance carriers, consumer-driven plans and third-party administrators.

Ben Wolin, chairman of the board, said, 'We are pleased to welcome Brian to the Diplomat team at this important time, and are confident that his dynamic skillset and significant industry experience make him ideally suited to assume the roles of CEO and chairman. Brian is a proven healthcare executive having served in various leadership roles for many years, including at Express Scripts, Empire BlueCross BlueShield and Anthem, most recently launching its PBM organisation. He brings expertise in areas essential to Diplomat's continued growth and success, including a tremendous knowledge of the PBM and specialty pharmacy industries and a deep understanding of the complexities and trends shaping the healthcare environment. His deep experience in Health Plan leadership will be instrumental in leading Diplomat in the rapidly evolving healthcare environment. On behalf of my fellow board members, we look forward to the next stage of the company's growth under Brian's leadership and are enthusiastic about the opportunities ahead.'